Prime Medicine (PRME) Non-Current Assets (2021 - 2026)
Prime Medicine (PRME) posted Non-Current Assets of $156.8 million for Q1 2026, down 2.85% on a QoQ basis from $161.4 million in Q4 2025, and down 4.6% year-over-year from $164.4 million in Q1 2025.
Prime Medicine (PRME) Non-Current Assets (2021 - 2026) Analysis & Trends
Prime Medicine's Non-Current Assets history runs 6 years deep, the most recent figure standing at $156.8 million for Q1 2026.
- Quarterly Non-Current Assets fell 4.6% year-over-year to $156.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.6 million (up 47.92% YoY) and the FY2025 annual result came in at $161.4 million, up 88.55% from the prior year.
- Non-Current Assets was $156.8 million for Q1 2026 at Prime Medicine, down from $161.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $164.4 million in Q1 2025 and bottomed at $50.9 million in Q4 2023.
- A 5-year average of $100.7 million and a median of $86.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 103.65% — and 2023, when it slipped 20.13%.
- Prime Medicine's Non-Current Assets stood at $63.7 million in 2022, then retreated by 20.13% to $50.9 million in 2023, then soared by 68.3% to $85.6 million in 2024, then surged by 88.55% to $161.4 million in 2025, then slipped by 2.85% to $156.8 million in 2026.
- Business Quant data shows PRME's Non-Current Assets at $156.8 million in Q1 2026, $161.4 million in Q4 2025, and $153.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | 156.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.84 Mn |
| Dec 31, 2025 | 161.44 Mn |
| Sep 30, 2025 | 153.61 Mn |
| Jun 30, 2025 | 157.72 Mn |
| Mar 31, 2025 | 164.40 Mn |
| Dec 31, 2024 | 85.62 Mn |
| Sep 30, 2024 | 86.71 Mn |
| Jun 30, 2024 | 88.90 Mn |
| Mar 31, 2024 | 93.73 Mn |
| Dec 31, 2023 | 50.88 Mn |
| Sep 30, 2023 | 54.61 Mn |
| Jun 30, 2023 | 62.38 Mn |
| Mar 31, 2023 | 63.45 Mn |
| Dec 31, 2022 | 63.70 Mn |
| Sep 30, 2022 | 66.42 Mn |
| Dec 31, 2021 | 31.28 Mn |